Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-24 pm EDT
37.68 USD   +1.87%
03/23Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/23Ultragenyx Pharmaceutical Inc. Announces Retirement of Lars Ekman as Board of Directors
CI
03/22Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

01/04/2023 | 06:01am EDT

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors  
Joshua Higa 
ir@ultragenyx.com  

Media  
Jeff Blake 
415-612-7784 
media@ultragenyx.com 


All news about ULTRAGENYX PHARMACEUTICAL INC.
03/23Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/23Ultragenyx Pharmaceutical Inc. Announces Retirement of Lars Ekman as Board of Directors
CI
03/22Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
03/21Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
03/14Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/14Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
GL
03/14Ultragenyx Pharmaceutical Inc. Appoints Dr. Eric Crombez Chief Medical Officer and Exec..
CI
03/07Transcript : Ultragenyx Pharmaceutical Inc. Presents at Cowen 43rd Annual Hea..
CI
03/01Ultragenyx pharmaceutical to participate in orphan neuro panel at cowen healthcare conf..
AQ
02/28Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
GL
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2023 435 M - -
Net income 2023 -562 M - -
Net cash 2023 471 M - -
P/E ratio 2023 -4,81x
Yield 2023 -
Capitalization 2 646 M 2 646 M -
EV / Sales 2023 5,00x
EV / Sales 2024 4,27x
Nbr of Employees 1 311
Free-Float 94,9%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 37,68 $
Average target price 90,58 $
Spread / Average Target 140%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Samuel C. Wadsworth Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-18.67%2 646
REGENERON PHARMACEUTICALS, INC.13.65%87 515
VERTEX PHARMACEUTICALS8.87%80 827
WUXI APPTEC CO., LTD.-1.06%34 805
BIONTECH SE-14.66%31 155
GENMAB A/S-12.34%24 291
Stock markets for all
100% Free Registration
fermer